Drug development pipeline
The MTC-B7 mixture supporting breast cancer treatment was created on the basis of the transdermal therapeutic system MTC-Y enriched with natural absorption promoters and extracts of active substances. Thanks to the simultaneous application of the deep penetrating transdermal system and specific, selective absorption promoters, it is possible to transport active substances inhibiting the proliferation of pathologically changed tissues. As a result of technological solutions applied, a preparation has been created that softens solid tumour tissues, at the same time sensitizing them to the action of anticancer substances.
The MTC-U1 mixture is an original drug for the treatment of bedsores and ulcers of the lower extremities. With the therapeutic system thus developed it is possible to inhibit inflammatory conditions, stop local development of infections and support natural tissue regeneration processes. The MTC-U1 mixture is based on natural active substances, a multiphase, semi-solid form of the drug with an increased bioavailability and a modified release profile. The result of the solutions applied is a cheaply produced anti-inflammatory preparation, accelerating the regeneration of healthy tissues and having a wide range of applications, e.g. on skin inflammations, ulcers, decubitus ulcers, and wounds that are difficult to heal.
The MTC-A4 mixture is an original topical anesthetic offering an increased bioavailability and permeability through skin layers. Thanks to the technology used in MTC-A4, it is possible to target the action of topical anesthetics on nerve endings located in the spinous layer of the skin and nerves in the dermis. The effect of the applied MTC-A4 solutions offers about 10 times stronger local action compared to anesthetics available on the market.